Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 19/20 | 0.51 |
| ▸ | PSEN2 | P49810 | 19/20 | 0.51 |
| ▸ | APH1B | Q8WW43 | 19/20 | 0.51 |
| ▸ | NCSTN | Q92542 | 19/20 | 0.51 |
| ▸ | APH1A | Q96BI3 | 19/20 | 0.51 |
| ▸ | PSENEN | Q9NZ42 | 19/20 | 0.51 |
| ▸ | APP | P05067 | 12/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2271918 | 0.81 | PSEN1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL21179376 | 0.80 | PSEN1 (0.52) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL21374341 | 0.80 | RIPK1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL23413486 | 0.80 | APP (0.51) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL22494480 | 0.80 | APP (0.51) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL29743515 | 0.80 | APP (0.51) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL21326188 | 0.78 | PSEN1 (0.53) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL22494453 | 0.78 | APP (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL27017005 | 0.77 | APP (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL722585 | 0.74 | PSEN1 (0.49) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728262-B1 | TRIAZOLO-AZEPINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-03-15 | — | — | EP | disclosed |
| US-11440915-B2 | Triazolo-azepine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2022-09-13 | — | — | US | disclosed |
| EP-3728262-A1 | TRIAZOLO-AZEPINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2020-10-28 | — | — | EP | disclosed |
| US-20200317681-A1 | TRIAZOLO-AZEPINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-20200317681-A1 | TRIAZOLO-AZEPINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317681-A1 | TRIAZOLO-AZEPINE DERIVATIVES | HUWE1, APP, PSEN1 | PSEN1 3/4885PSEN2 8/4885APH1B 60/4885 |
| US-11440915-B2 | Triazolo-azepine derivatives | HUWE1, PSEN1, UPF1 | PSEN1 2/4885PSEN2 7/4885APH1B 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.